Mar. Drugs 2014, 12(2), 851-870; doi:10.3390/md12020851

Fucoidan as a Marine Anticancer Agent in Preclinical Development

Received: 15 November 2013; in revised form: 31 December 2013 / Accepted: 10 January 2014 / Published: 28 January 2014
(This article belongs to the Special Issue Marine Compounds and Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Fucoidan is a fucose-containing sulfated polysaccharide derived from brown seaweeds, crude extracts of which are commercially available as nutritional supplements. Recent studies have demonstrated antiproliferative, antiangiogenic, and anticancer properties of fucoidan in vitro. Accordingly, the anticancer effects of fucoidan have been shown to vary depending on its structure, while it can target multiple receptors or signaling molecules in various cell types, including tumor cells and immune cells. Low toxicity and the in vitro effects of fucoidan mentioned above make it a suitable agent for cancer prevention or treatment. However, preclinical development of natural marine products requires in vivo examination of purified compounds in animal tumor models. This review discusses the effects of systemic and local administration of fucoidan on tumor growth, angiogenesis, and immune reaction and whether in vivo and in vitro results are likely applicable to the development of fucoidan as a marine anticancer drug.
Keywords: fucoidan; anticancer; preclinical; anticancer immunity; antiangiogenesis
PDF Full-text Download PDF Full-Text [765 KB, uploaded 28 January 2014 14:12 CET]

Export to BibTeX |

MDPI and ACS Style

Kwak, J.-Y. Fucoidan as a Marine Anticancer Agent in Preclinical Development. Mar. Drugs 2014, 12, 851-870.

AMA Style

Kwak J-Y. Fucoidan as a Marine Anticancer Agent in Preclinical Development. Marine Drugs. 2014; 12(2):851-870.

Chicago/Turabian Style

Kwak, Jong-Young. 2014. "Fucoidan as a Marine Anticancer Agent in Preclinical Development." Mar. Drugs 12, no. 2: 851-870.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert